Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States

被引：0
|
作者：
Khalid, Javaria Mona [1 ]
Raluy-Callado, Mireia [2 ]
Li, Qian [3 ]
Luo, Michelle [4 ]
Lasch, Karen [4 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, London, England
[2] Evidera, London, England
[3] Evidera, Lexington, MA USA
[4] Takeda Pharmaceut USA Inc, Deerfield, IL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
700
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [21] Gastroenterology Vedolizumab as an Option in ulcerative Colitis and Crohn's Disease?
    Pommer, Peter
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (45) : 2284 - 2284
  • [22] Current position on Vedolizumab for ulcerative colitis and Crohn's disease
    Schreiber, S.
    Dignass, A. U.
    Hartmann, H.
    Kruis, W.
    Rogler, G.
    Siegmund, B.
    Stallmach, A.
    Witte, C.
    Bokemeyer, B.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (06): : 591 - 602
  • [23] DISCONTINUATION OF CORTICOSTEROIDS AMONG ULCERATIVE COLITIS PATIENTS TREATED WITH VEDOLIZUMAB IN THE UNITED STATES (US)
    Patel, Haridarshan
    Chastek, Benjamin
    Null, Kyle D.
    Demuth, Dirk
    GASTROENTEROLOGY, 2017, 152 (05) : S396 - S397
  • [24] Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
    Hagan, Matilda
    Cross, Raymond K.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) : 1473 - 1479
  • [25] Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
    Gilroy, Leah
    Allen, Patrick B.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 163 - 172
  • [26] VEDOLIZUMAB DOSE ESCALATION IMPROVES DISEASE ACTIVITY FOR "PARTIAL RESPONDERS" IN ULCERATIVE COLITIS
    Perry, Courtney
    Fischer, Kyle
    Elmoursi, Ahmed
    Su, Leon
    Kern, Cody
    Currier, Alden C.
    Kudaravalli, Praneeth
    Yarra, Pradeep
    Tripathi, Nishant
    Akanbi, Olalekan
    Abdelsalam, Mohammed
    Barrett, Terrence
    GASTROENTEROLOGY, 2020, 158 (06) : S965 - S965
  • [27] CORTICOSTEROID DOSE REDUCTION IN ULCERATIVE COLITIS PATIENTS TREATED WITH VEDOLIZUMAB
    Loftus, E.
    Siegel, C.
    Panaccione, R.
    Sandborn, W.
    Smyth, M.
    James, A.
    Xu, J.
    Abhyankar, B.
    GUT, 2016, 65 : A254 - A255
  • [28] Is there a difference in trough levels and immunogenicity between Crohn's disease and ulcerative colitis patients treated with infliximab?
    Perdigoto, D.
    Macedo, C.
    Portela, F.
    Lopes, S.
    Ferreira, M.
    Ferreira, M.
    Mendes, S.
    Tome, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S475 - S475
  • [29] COST BURDEN OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN THE UNITED STATES
    Chen, C.
    Xiao, H.
    VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
  • [30] Patients with Crohn's disease treated with ustekinumab vs. vedolizumab in real-world settings
    Chiorean, M.
    Jiang, J.
    Candela, N.
    Chen, G.
    Romdhani, H.
    Latremouille-Viau, D.
    Shi, S.
    Bungay, R.
    Fan, T.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S630 - S630
12345